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Background In Spain, listing for high-urgent heart transplantation is allowed for critically ill candidates not weanable from
temporary mechanical circulatory support (T-MCS). We sought to analyse the clinical outcomes of this strategy.
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Methods
and results
We conducted a case-by-case, retrospective review of clinical records of 291 adult patients listed for high-urgent
heart transplantation under temporary devices from 2010 to 2015 in 16 Spanish institutions. Survival after listing
and adverse clinical events were studied. At the time of listing, 169 (58%) patients were supported on veno-arterial
extracorporeal membrane oxygenation (VA-ECMO), 70 (24%) on temporary left ventricular assist devices (T-LVAD)
and 52 (18%) on temporary biventricular assist devices (T-BiVAD). Seven patients transitioned from VA-ECMO to
temporary ventricular assist devices while on the waiting list. Mean time on T-MCS was 13.1± 12.6 days. Mean time
from listing to transplantation was 7.6± 8.5 days. Overall, 230 (79%) patients were transplanted and 54 (18.6%) died
during MCS. In-hospital postoperative mortality after transplantation was 33.3%, 11.9% and 26.2% for patients bridged
on VA-ECMO, T-LVAD and T-BiVAD, respectively (P= 0.008). Overall survival from listing to hospital discharge was
54.4%, 78.6% and 55.8%, respectively (P= 0.002). T-LVAD support was independently associated with a lower risk
of death over the first year after listing (hazard ratio 0.52, 95% confidence interval 0.30–0.92). Patients treated with
VA-ECMO showed the highest incidence rate of adverse clinical events associated with T-MCS.
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Conclusion Temporary devices may be used to bridge critically ill candidates directly to heart transplantation in a setting of short
waiting list times, as is the case of Spain. In our series, bridging with T-LVAD was associated with more favourable
outcomes than bridging with T-BiVAD or VA-ECMO.
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Introduction
In recent years, shortage of donors and long waiting list times
resulted in a progressive increase of the number of candidates
who are bridged to heart transplantation (HT) under mechanical
circulatory support (MCS), most of them by means of durable left
ventricular assist devices (LVADs).1,2
Durable LVADs provide their best clinical outcomes when
implanted in stable patients with isolated left ventricular failure.
Survival after LVAD implantation slips early in patients requiring
biventricular support, and in those operated in the course of acute
decompensation.2 Durable LVAD implantation is discouraged in
patients with cardiogenic shock, who at a first step are more safely
treated with temporary devices.3
Further management of patients recovering from cardiogenic
shock under temporary MCS (T-MCS), otherwise considered
suitable candidates for HT, remains a clinical challenge. Facing this
situation, many teams would consider the transition from T-MCS
to a durable LVAD as a bridge to HT; however, this ‘double bridge’
strategy has concerning results.4 As an alternative option, an
expedite pathway to high-urgent HT is enabled for such individuals
in some countries.
Globally, the use of T-MCS as a direct bridge to HT is an unusual
resort.1 However, in Spain this is the most common mode of
bridging.5 Reasons for this particularity of our country are both
tight economic restrictions on access to durable LVADs and quick
availability of donors that allows such an approach. The experience
of Spanish teams with the use of T-MCS as a direct bridge to HT
gives a unique opportunity to deepen knowledge about the clinical
results of this rather unusual strategy.
Methods
Setting
In Spain, the procurement and distribution of organ donors is coor-
dinated by the Organización Nacional de Trasplantes (ONT), a public
healthcare network that integrates all hospitals with capability for organ
extraction or implantation around the country. In 2010, heart graft
distribution criteria were modified,6 and following that date the high-
est level of waiting list priority, the so-called ‘ONT status 0’, is granted
exclusively to HT candidates not weanable from T-MCS, or to those
who develop complications related to durable ventricular assist devices
(VADs)—infection, pump failure, or thrombosis. ONT status 0 con-
fers priority over all other candidates nationwide to receive the first
suitable donor heart available in the system—i.e. high-urgent HT.
Temporary devices2 that qualify for ONT status 0 are those
intended to provide full circulatory support for a maximum period
of days or a few weeks, only at the in-hospital setting. Central
or peripheral veno-arterial extracorporeal membrane oxygenation
(VA-ECMO), percutaneous LVADs (e.g. Impella Recover®), and
surgically implanted, extracorporeal continuous-flow VADs (e.g.
Levitronix CentriMag®, Maquet Rotaflow®, Sorin Revolution®),
or extracorporeal pulsatile-flow VADs (e.g. Abiomed AB 5000®,
Abiomed BVS 5000®) meet these definition criteria. Devices intended
for medium- or long-term, out-of-hospital circulatory support, either
paracorporeal (e.g. BerlinHeart Excor®) or intracorporeal (e.g.



















































































.. candidates listed on these modalities of MCS do not qualify as ONT
status 0, unless in case of device-related complications. Intra-aortic bal-
loon pump (IABP) is specifically excluded from the definition of T-MCS.
Study design
The ASIS-TC study (‘Empleo de los dispositivos de ASIStencia circulatoria
mecánica de corta duración como puente a Trasplante Cardiaco urgente
en España’, in English ‘Use of short-term mechanical circulatory support
devices as a bridge to urgent heart transplantation in Spain’) was a
nationwide retrospective registry which included all patients listed
for first, single-organ, high-urgent HT (ONT status 0) under T-MCS
in Spain from 1 January 2010 to 31 December 2015. Patients aged
<18 years, those listed for multi-organ transplantation or second HT,
and those listed due to durable VAD-related complications were
excluded.
Patients eligible for the registry were identified by means of the
ONT database. A case-by-case retrospective review of medical records
of all study subjects was conducted locally at every one of the 16
transplant centres of the country. Selected information regarding
donors and post-transplant survival was extracted from the Spanish
Heart Transplantation Registry.5
Pre- and post-transplant survival and adverse clinical events were
analysed, both in the entire cohort and with regard to different modal-
ities of T-MCS—temporary LVAD (T-LVAD), temporary biventricular
assist device (T-BiVAD), or VA-ECMO. Definitions of study outcomes
are detailed in the Supplementary material online, Methods S1.
The study protocol was approved by the Committee for Ethics in
Clinical Investigation of the Autonomous Community of Galicia, Spain,
and ratified by institutional review boards of participating hospitals.
Statistical analysis
Continuous variables are presented as mean± standard deviation
and categorical variables are presented as proportions. ANOVA and
chi-square tests were used for statistical comparisons among groups,
as required. The Clopper–Pearson exact method was used to estimate
95% confidence intervals (CI) of incidence rates of study outcomes.
One-year survival curves after high-urgent transplant listing were
estimated by means of the Kaplan–Meier method and compared by
means of the log-rank test. Independent predictors of 1-year survival
after listing were identified by means of multivariable backward step-
wise Cox regression analysis, choosing a “P-out” criterion of <0.05.
Candidate variables selected for the model were those reflecting base-
line clinical characteristics of patients at the time of listing that showed
a statistically significant association with 1-year survival in univariable
analyses. Statistical significance was set at P< 0.05 for all comparisons.
Statistical analyses were performed with SPSS 20 (SPSS Inc., Chicago,
IL, USA) and EpiDat 4.1.
Results
Patients and devices
During the study period, 291 patients were listed for high-urgent
HT (ONT status 0) while on T-MCS in 16 Spanish institutions.
At the time of listing, 169 (58%) patients were on VA-ECMO, 70
(24%) patients had a T-LVAD and 52 (18%) patients had a T-BiVAD.
Before the instauration of T-MCS, 79 (27.1%) patients had been
already listed for HT with a priority level inferior to status 0,
© 2017 The Authors
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Table 1 Devices in place at the time of high-urgent
listing
Devices Patients, n
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
VA-ECMO 169 (58%)
Peripheral insertion, femoral arterya 144









Abiomed BVS 5000c 14
Abiomed AB 5000c 1
Sorin Revolutionb 1
T-BiVAD, temporary biventricular assist device; T-LVAD, temporary left ventric-





so they upgraded to the high-urgent level after the intervention.
Table 1 shows temporary devices in place at the time of high-urgent
listing.
Seven patients listed on T-BiVADs and 5 patients listed on
T-LVADs had been previously treated with VA-ECMO, but not
listed while on it. Also, 2 patients listed on VA-ECMO have been
previously treated with a T-LVAD, but not listed while on it.
Before T-MCS instauration, 168 (58%) patients had an IABP, which
remained in place at the time of high-urgent listing in 104 (35%)
cases.
Table 2 shows the baseline clinical characteristics of the study
patients at the time of high-urgent listing according to the modality
of T-MCS. Patients on VA-ECMO more frequently presented with
Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS)7 profile 1, more frequently had antecedents of
open-chest surgery, and more frequently required ancillary vital
supportive therapies like IABP and mechanical ventilation; this
subgroup also showed the shortest time from device insertion to
listing. The prevalence of active infection at listing was lower among
VA-ECMO candidates.
Outcomes during temporary mechanical
circulatory support
Mean duration of T-MCS was 13.1± 12.6 days (range 0–94 days),
with significant differences among modalities of support
(T-LVAD: 18.1±15.9 days; T-BiVAD: 15.9±15.8 days; VA-ECMO:
9.6± 8 days; P< 0.001). While awaiting transplantation, 7 patients
listed initially on VA-ECMO transitioned to T-VADs—5 Levit-
ronix CentriMag® BiVAD, 1 Levitronix CentriMag® LVAD, and 1



















































































.. Overall, 230 (79%) patients were transplanted while on T-MCS
and 54 (18.6%) died before transplantation. Mean time from
high-urgent listing to HT was 7.6± 8.5 days (range 0–81 days),
varying significantly among modalities of support (T-LVAD:
8.3± 8.1 days; T-BiVAD: 10.5± 3.4 days; VA-ECMO: 6.5± 6.2 days;
P= 0.024).
Rates of transplantation during support were 84.3%, 75% and
78.1% in patients listed on T-LVADs, T-BiVADs, and VA-ECMO,
respectively (P= 0.414). Rates of death during support (before
transplantation) were 11.4%, 25% and 19.5%, respectively
(P= 0.143).
Only 7 (2.4%) patients were weaned from T-MCS. Of them,
three were discharged after durable VAD implantation, one was
discharged after elective HT, and three were discharged on medical
therapy.
Figure 1 shows a flow chart of patients, devices and in-hospital
outcomes in the study population. Figure 2 shows a representation
of competing outcomes of death on T-MCS, transplantation on
T-MCS, or weaning from T-MCS over a 4-week period after listing.
Postoperative outcomes after
transplantation
Table 3 shows donor characteristics and major in-hospital postop-
erative outcomes in 230 patients transplanted while on T-MCS.
Cumulative rates of in-hospital post-transplant mortality were
33.3%, 26.2% and 11.9% in recipients bridged on VA-ECMO,
T-BiVADs or T-LVADs, respectively (P= 0.008). No statistically sig-
nificant differences among groups were observed with regard to
other postoperative outcomes.
Overall 1-year outcomes after listing
In the whole cohort, 176 (60.5%) patients listed for high-urgent
HT were discharged alive from hospital. Cumulative rates of sur-
vival from listing to hospital discharge in patients with T-LVADs,
T-BiVADs and VA-ECMO were 78.6%, 55.8% and 54.4%, respec-
tively (P= 0.002).
Figure 3 shows Kaplan–Meier survival curves over the first year
after high-urgent listing of patients treated with different modali-
ties of T-MCS (log-rank P= 0.010). In multivariable Cox regression,
age, vasoactive-inotropic score,8 serum lactate levels, active infec-
tion, and renal replacement therapy at the time of listing were
independent predictors of mortality; isolated T-LVAD support was
independently associated with higher survival. Univariable and mul-
tivariable Cox regression analyses are detailed in Table 4.
Adverse clinical events associated
with temporary mechanical circulatory
support
The overall incidence rate of adverse clinical events associated with
T-MCS was 59 (95% CI 52–68) per 1000 devices-day (Table 5).
In comparison to T-LVAD patients, VA-ECMO patients presented
a statistically significant higher incidence rate of adverse clinical
© 2017 The Authors
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Table 2 Clinical characteristics of the study patients at the time of high-urgent listing
Variables T-LVAD (n= 70) T-BiVAD (n= 52) VA-ECMO (n=169) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical history
Age (years) 52±12 52± 10 50±13 0.517
Female sex 22.9% 23.1% 24.3% 0.967
Body mass index (kg/m2) 25± 4 26± 4 26± 5 0.313
Days from hospital admission to device insertion 10± 15 14± 22 12± 20 0.440
Days from device insertion to high-urgent listing 11±14 7± 9 3± 5 <0.001
Patients in waiting list prior to device insertion 28.6% 23.1% 27.8% 0.948
Ischaemic heart disease 61.4% 44.2% 53.3% 0.168
Cardiogenic shock related to acute myocardial infarction 47.1% 25.0% 32% 0.023
Cardiogenic shock following cardiac surgery 4.3% 13.5% 10.1% 0.194
Diabetes mellitus 15.7% 23.1% 25.4% 0.262
Hypertension 24.3% 34.6% 33.1% 0.344
Hypercholesterolaemia 30% 36.5% 33.1% 0.748
Previous open-chest cardiac surgery 8.6% 15.4% 26.6% 0.004
History of malignancy 4.3% 5.8% 1.2% 0.139
Peripheral vascular disease 7.1% 1.9% 5.9% 0.427
Chronic obstructive pulmonary disease 14.3% 7.7% 4.1% 0.022
Previous stroke 4.3% 1.9% 7.1% 0.315
History of ventricular arrhythmia 25.7% 25% 27.2% 0.938
History of atrial fibrillation 15.7% 19.2% 22.5% 0.485
Previous cardiac arrest 14.3% 9.6% 17.2% 0.404
Implantable cardioverter-defibrillator 28.6% 23.1% 26% 0.791
Cardiac resynchronization therapy 8.6% 9.6% 11.8% 0.732
Active infection requiring i.v. therapy 18.6% 19.2% 6.5% 0.005
Clinical status
INTERMACS profile 0.003
INTERMACS 1 24.3% 26.9% 42.6%
INTERMACS 2 54.3% 50% 49.1%
Other 21.4% 23.1% 8.3%
Systolic blood pressure (mmHg) 98±15 97± 9 102± 20 0.191
Heart rate (b.p.m.) 99±17 89± 20 98± 22 0.027
Supportive therapies
Intra-aortic balloon pump 21.4% 30.8% 43.2% 0.004
Renal replacement therapy 11.4% 11.5% 7.1% 0.435
Mechanical ventilation 38.6% 61.5% 77.5% <0.001
Vasoactive-inotropic score (units) 27± 71 24± 76 43± 66 0.129
Laboratory
Leucocytes (x109/L) 12.0± 5.1 11.8± 4.2 12.5± 5.5 0.576
Platelets (x109/L) 180±103 183± 89 185± 81 0.893
INR 1.6± 0.7 1.3± 0.3 1.6± 0.8 0.321
Prothrombin time (s) 20±13 17± 6 20±10 0.593
Creatinine (mg/dL) 1.1± 0.9 1.3± 0.5 1.4± 0.8 0.051
Haemoglobin (g/dL) 9.5±1.4 9.3± 1.4 10.5± 2 <0.001
Sodium (mEq/L) 138± 5 139± 6 139± 8 0.172
Bilirubin (mg/dL) 1.2± 1.1 1.6±1.8 1.9± 2.3 0.057
Aspartate aminotransferase (IU/L) 92±139 228± 482 302± 697 0.063
Alanine aminotransferase (IU/L) 78±119 148± 279 318± 718 0.015
Albumin (g/dL) 3.0± 0.7 2.9± 0.6 3.0± 0.8 0.596
Arterial oxygen tension (mmHg) 110± 54 105± 37 117± 50 0.302
pH 7.4± 0.1 7.4± 0.1 7.4± 0.1 0.171
Lactate (mmol/L) 1.6± 1.7 2.1± 2.3 2.4± 2.2 0.090
Echocardiography
Left ventricular ejection fraction (%) 22± 9 25± 12 23±13 0.358
Left ventricular end-systolic diameter (mm) 67±12 62± 10 61±13 0.049
Tricuspid annular plane systolic excursion (mm) 15± 4 15± 4 14± 5 0.136
Haemodynamics
Cardiac index (mL/min/m2) 2.4± 0.6 2.3± 0.7 2.1± 0.8 0.028
Central venous pressure (mmHg) 14± 5 12± 6 14± 6 0.316
Capillary wedge pressure (mmHg) 21± 8 21± 9 23± 9 0.450
Mean pulmonary pressure (mmHg) 26± 8 30± 15 30±12 0.217
Transpulmonary gradient (mmHg) 8± 6 11± 8 8± 5 0.108
INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; T-BiVAD, temporary biventricular assist device; T-LVAD,
temporary left ventricular assist device; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
© 2017 The Authors
European Journal of Heart Failure © 2017 European Society of Cardiology




   
   
   
   
   
   
   
   
   















   
   
   
   
   
   
















   
   
   
   
   
   
   



















   
   
   
   
   



















   
   
   
   



















   
   
   
   

































   
   
   
   
   
   












   
   
   
   
   
   
   

















   
   











   
   
   
   
   
   
   








   
   
   
   



















   
   
   
   















   
   
   
   
   
   
   
   















   
   
   
   
   
   
   
   
   


























   
   
   
   
   
   













   
   
   
   
   
   
   
   
   
   
















   
   
   
   
   
































   
   
   
   
   
   
   
   

















   
   
   
   
   














   
   
   
   
   















   
   
   
   
   














   
   
   
   
   
   
   
   
   
















   
   
   
   



















   
   
   
















   
   
   
   
   
   
   
















































   
   
   
   
   
   
   

























































































































































































































© 2017 The Authors
European Journal of Heart Failure © 2017 European Society of Cardiology






0 7 14 21 28 
Alive (on support) 
Transplanted 
Died (before transplant) 
Weaned 















Figure 2 Depiction of the competing outcomes analysis for
death, weaning or transplantation during a 28-day follow-up
period after listing. At any given time point, the sum of the
proportion of patients experiencing each outcome equals 100%.
ONT, Organización Nacional de Trasplantes.
events (71 vs. 47 events per 1000 devices-day, risk ratio 1.52,
P= 0.008). The incidence rate of adverse clinical events among
T-BiVAD patients was numerically, but not statistically significant,
higher than among T-LVAD patients (57 vs. 47 events per 1000
devices-day, risk ratio 1.22, P= 0.303). Statistical comparisons of
the individual incidence rates of all adverse clinical events among
different modalities of T-MCS are presented in the Supplementary
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Figure 3 Kaplan–Meier depiction of survival over the first year
after high-urgent listing, according to different modalities of cir-
culatory support. ONT, Organización Nacional de Trasplantes;
T-BiVAD, temporary biventricular assist device; T-LVAD, tempo-
rary left ventricular assist device; VA-ECMO, veno-arterial extra-
corporeal membrane oxygenation.
The incidence rate of major adverse clinical events (device dys-
function, stroke, bleeding, or infection) was 50 (95% CI 43–58) per
1000 devices-day, without statistically significant differences among
modalities of support (T-LVAD: 41 events per 1000 devices-day,
T-BiVAD: 54 events per 1000 devices-day, VA-ECMO: 56 events
per 1000 devices-day; P> 0.005 for all comparisons). Supplemen-
tary Figure S1 shows the Kaplan–Meier depiction of survival free
of major adverse clinical events in the study population.
Table 3 Donor characteristics and in-hospital postoperative outcomes after heart transplantation
All patients (n= 230) T-LVAD (n= 59) T-BiVAD (n= 42) VA-ECMO (n= 129) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Donor characteristics
Female donor 59 (26%) 13 (22%) 11 (27%) 35 (26%) 0.756
Age (years) 42±12 42± 13 43± 12 42±11 0.958
Cold ischaemic time (min) 214± 60 213± 56 232± 46 209± 65 0.101
In-hospital postoperative outcomes
Excessive surgical bleeding 72 (31%) 15 (25%) 18 (43%) 39 (30%) 0.163
Primary graft failure 75 (33%) 16 (27%) 17 (41%) 42 (33%) 0.369
Right ventricular failure 41 (18%) 7 (12%) 10 (24%) 24 (19%) 0.645
Left ventricular or biventricular failure 34 (15%) 9 (15%) 7 (17%) 18 (14%) 0.422
T-MCS after transplant 34 (15%) 7 (12%) 6 (14%) 21 (16%) 0.729
Open-chest redo surgery 40 (17%) 6 (10%) 10 (24%) 24 (19%) 0.176
Renal failure 64 (28%) 15 (25%) 15 (36%) 34 (26%) 0.447
Postoperative infection 121 (53%) 32 (54%) 23 (55%) 66 (51%) 0.883
In-hospital postoperative death 61 (26%) 7 (12%) 11 (26%) 43 (33%) 0.008
Days on ventilator after transplant 11±17 8± 9 10±14 13± 21 0.196
Days of ICU stay after transplant 18±18 16± 22 20± 19 18±19 0.725
Days of hospital stay after transplant 38± 37 36± 29 39± 34 38± 40 0.930
ICU, intensive care unit; T-BiVAD, temporary biventricular assist device; T-LVAD, temporary left ventricular assist device; T-MCS, temporary mechanical circulatory support;
VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
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Table 4 Clinical predictors of 1-year all-cause mortality: univariable and multivariable Cox proportional hazards
regression
Univariable analysis Multivariable analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unadjusted HR 95% CI P-value Adjusted HR 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (per 10 years) 1.21 1.03–1.42 0.023 1.29 1.06–1.56 0.010
Vasoactive-inotropic score (per 10 units) 1.03 1.06–1.09 <0.001 1.07 1.04–1.10 <0.001
Creatinine (mg/dL) 1.33 1.10–1.60 0.004 – – –
Lactate (mmol/L) 1.11 1.03–1.21 0.009 1.10 1.00–1.20 0.049
Renal replacement therapy 2.22 1.35–3.67 <0.001 2.02 1.06–3.84 0.032
Isolated LVAD support 0.47 0.29–0.78 0.003 0.52 0.30–0.92 0.025
Mechanical ventilation 1.67 1.12–2.49 0.012 – – –
Intra-aortic balloon pump 1.48 1.03–2.12 0.033 – – –
Active infection requiring i.v. therapy 1.74 1.08–2.02 0.023 2.13 1.20–2.79 0.010
INTERMACS profile 1 2.03 1.42–2.90 <0.001 – – –
CI, confidence interval; HR, hazard ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device.
Patients who experienced major adverse clinical events associ-
ated with T-MCS showed lower rates of transplantation (71.7% vs.
92.3%, P< 0.001), higher rates of death during support (25.1% vs.
6.7%, P< 0.001), lower survival from listing to hospital discharge
(55.1% vs. 70.2%, P= 0.012) and lower 1-year survival after listing
(52.5% vs. 66.5%, log-rank P= 0.011; see Supplementary material
online, Figure S2) than patients who did not.
Discussion
In this 16-institution study, we analysed the clinical outcomes
of 291 Spanish patients who were listed for high-urgent HT
while on T-MCS during the period 2010–2015. In a setting of
short waiting times, overall survival from listing to hospital dis-
charge was 61% and overall 1-year survival after listing was
58%. Patients bridged on T-LVADs presented better outcomes
than patients bridged on VA-ECMO or T-BiVADs. Adverse clin-
ical events associated with T-MCS were frequent in the study
population.
In our registry, the strategy of bridging patients directly to
high-urgent HT was associated with significant short-term mor-
tality, divided almost half-and-half between the waiting list period
and the early post-transplant period. Nevertheless, these results
must be put in the context of the critically ill population treated.
The majority of our patients showed INTERMACS profiles7 1 or 2,
with signs of profound haemodynamic compromise and end-organ
dysfunction, and frequently required ancillary supportive therapies
like mechanical ventilation, high-dose vasoactive drugs, or IABP. In
the absence of other efficient therapeutic alternatives, we feel that
these clinical results are in general terms acceptable, even though
they could be refined. However, it should be recognized that these
results were obtained by treating a selected population of young
HT candidates (mean age 51 years), with a relatively low preva-
lence of pre-existing adverse co-morbidities, in the context of a
reasonable availability of organ donors. This strategy might not be























































. It might be argued that durable VAD implantation as a bridge
to HT constitutes a better option than primary listing in can-
didates depending on T-MCS. However, published experience
with this ‘double-bridge’ strategy is limited, and with concerning
results. Two small American studies,5,9 conducted in 68 and 45
patients, respectively, who underwent HeartMate II® or Heart-
Ware HVAD® implantation while on T-MCS, reported con-
sistent 1-year postoperative survival rates of 70%. In another
single-centre European cohort of 20 patients who transitioned
from ECMO to Berlin Heart Excor®, 1-year postoperative sur-
vival was reduced to 40%.10 Some concern has been gener-
ated about a potential negative impact of preoperative long-term
MCS on post-transplant survival;11 however, post-transplant out-
comes of successfully bridged patients were not analysed in these
studies.5,9,10
Mean waiting time for transplantation was short in our series
(7.6 days), allowing that near 80% patients listed on T-MCS received
a graft. These figures reflect the efficient performance of the ‘ONT
status 0’ protocol, comparable to UNOS status 1A,12 and superior
to Eurotransplant high-urgency.13 Details about the organization
and functioning of our national organ donor-sharing network have
been described previously.14
Clinical complications associated with T-MCS were common
in our population. The overall incidence rate of adverse events
was near 6% per patient and day on support; daily risks of
infection and serious bleeding were around 3%, while daily risks
of stroke and device dysfunction exceeded 0.5%. Vascular access
site complications requiring local intervention were frequent in
patients with percutaneous devices; renal replacement therapy
and open-chest redo surgery were also occasionally needed. Even
despite a liberal use of concomitant IABP support,15 daily rates of
acute pulmonary oedema were as higher as 1.5% in patients treated
with VA-ECMO. Incidence rates of adverse events were consistent
with those described in other registries,16,17 and substantially
higher than those reported in patients with durable devices.2 Not
surprisingly, complications associated with T-MCS had a significant
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Table 5 Incidence rates of clinical complications associated with temporary mechanical circulatory support,
expressed as number of subjects having an event per 1000 device-days on support
All devices (n= 298) T-LVAD (n= 72) T-BiVAD (n= 57) VA-ECMO (n= 169)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
N Rate (95% CI) N Rate (95% CI) N Rate (95% CI) N Rate (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Infection 120 32 (26–38) 36 28 (19–38) 32 36 (25–52) 52 32 (24–42)
Bleeding 118 31 (26–37) 32 25 (17–35) 29 33 (22–47) 57 35 (27–45)
Vascular access site complicationa 41 26 (18–35) 4 59 (52–68) – – 37 24 (17–34)
Venous thromboembolism 6 2 (1–3) 0 0 0 0 6 4 (1–8)
Non-CNS arterial thromboembolism 15 4 (2–6) 0 0 5 6 (2–13) 10 6 (3–11)
Stroke 23 6 (4–9) 9 7 (3–13) 6 7 (3–15) 8 5 (2–10)
Renal failure 59 16 (12–20) 18 14 (8–22) 13 15 (8–25) 28 17 (11–25)
Open-chest redo surgeryb 40 18 (13–25) 21 17 (11–26) 18 21 (12–32) 1 9 (0–52)
Pleural effusion 31 8 (6–12) 6 5 (2–10) 16 18 (10–30) 9 6 (3–11)
Pneumothorax 6 2 (1–3) 3 2 (0–6) 1 1 (0–6) 2 1 (0–4)
Pericardial effusion 26 7 (5–10) 10 8 (4–14) 7 8 (3–16) 9 6 (3–11)
Cardiac tamponade 20 5 (3–8) 9 7 (3–13) 5 6 (2–13) 6 4 (1–8)
Wound dehiscenceb 4 2 (0–5) 2 1 (0–5) 2 2 (0–8) 0 0
Right ventricular failurec 9 7 (3–13) 9 7 (3–13) – – – –
Acute pulmonary oedemad 25 15 (10–23) – – – – 25 15 (10–23)
Haemolysis 20 5 (3–8) 7 5 (2–11) 4 5 (1–12) 9 6 (3–11)
Device dysfunction 25 7 (4–10) 9 7 (3–13) 5 6 (2–13) 11 7 (3–12)
Device exchange or replacement 21 6 (3–8) 8 6 (3–12) 4 5 (1–12) 9 6 (3–11)
Major adverse clinical eventse 191 50 (43–58) 53 41 (30–53) 47 54 (40–71) 91 56 (45–69)
All adverse clinical events 226 59 (52–68) 61 47 (36–60) 50 57 (42–75) 115 71 (58–85)
CI, confidence interval; CNS, central nervous system; T-BiVAD, temporary biventricular assist device; T-LVAD, temporary left ventricular assist device; VA-ECMO, veno-arterial
extracorporeal membrane oxygenation.
aRates calculated only for percutaneous LVADs (n= 12) and peripheral VA-ECMO (n= 161).
bRates calculated only for surgically implanted LVADs (n= 60), surgically implanted BiVADs (n= 57), and central VA-ECMO (n= 8).
cRates calculated only for LVADs (n= 72).
dRates calculated only for VA-ECMO (n= 169).
eDevice dysfunction, infection, bleeding, or stroke.
impact on the chance of getting an organ and, subsequently, on
survival.
We observed relevant differences in clinical outcomes according
to the modality of T-MCS selected for bridging. Patients listed on
T-LVADs showed significant higher survival rates than those listed
on T-BiVADs or VA-ECMO. Patients of these two latter groups had
higher rates of complications associated with T-MCS while awaiting
transplantation; however, survival differences were driven mainly
by an excess of early post-transplant mortality, similarly to results
reported previously.18–20 Patients bridged on T-LVADs showed
comparable outcomes to those of medically managed patients who
undergo elective HT in our country.5 A glance to baseline clinical
characteristics reveals that the T-LVAD group represented a less
sick population than the rest of the cohort, a fact that probably has
conditioned these results.
Interestingly, patients supported with VA-ECMO showed the
shortest time since device implantation to listing and, subsequently,
to HT. This finding is a clear reflection of how the presumed dura-
bility of the device selected for bridging impacts the timing of clin-
ical decisions in critically ill HT candidates. It is probable, indeed,
that some VA-ECMO patients were listed, and then transplanted,
‘too early’, even before complete recovery of end-organ function


































. prolonged VA-ECMO support, such as insufficient left ventricular
unloading, pulmonary distress, or coagulopathy, may have jeopar-
dized post-transplant outcomes in candidates who did not get an
organ during the first days after being stabilized.
Our study has a few limitations. As a retrospective, observa-
tional investigation, it is exposed to potential selection, informa-
tion, and confusion biases. The study involved a wide variety of
institutions across Spain, with different centre-specific protocols,
volume of activity and clinical experience. Adverse clinical events
were self-reported by local investigators, without external moni-
toring; in some cases, this might lead to underestimation of their
incidence. Also, the limited number of patients analysed may have
prevented us to demonstrate as statistically significant some clin-
ically relevant results; in particular, this fact may have affected the
comparison of outcomes of patients bridged on different modali-
ties of T-MCS. Finally, our results may not apply to other networks
with longer waiting times for high-urgent HT and higher availability
of long-term MCS devices than the Spanish one.
In conclusion, the Spanish experience shows that the use of
T-MCS as a direct bridge to high-urgent HT is a feasible therapeutic
strategy in the context of an efficient donor allocation system
that ensures availability of a suitable graft for the patient within
a few days after listing. In our cohort, patients listed for HT
© 2017 The Authors
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under T-LVADs showed comparable outcomes to those reported
previously for medically managed candidates transplanted in our
country. A higher incidence of associated adverse clinical events
and mortality was observed among candidates listed on T-BiVADs
or VA-ECMO; nevertheless, clinical outcomes of these critically
ill individuals were, in general lines, acceptable, and similar to
those reported from other networks. Our observation, however,
might not be extensible to other countries with longer waiting
list times for transplantation. Further investigation is warranted to
clarify which is the best therapeutic option for the management of
critically ill HT candidates dependent on T-MCS.
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